Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct:224:71-77.
doi: 10.1016/j.trsl.2020.05.007. Epub 2020 Jun 3.

Innovative highlights of clinical drug trial design

Affiliations
Review

Innovative highlights of clinical drug trial design

Daohong Chen et al. Transl Res. 2020 Oct.

Abstract

Clinical trials serve as the gold standard to evaluate the efficacy and safety of tested drugs prior to marketing authorization. Nevertheless, there have been a few challenging issues well noted in traditional clinical trials such as tedious processing duration and escalating high costs among others. To improve the efficiency of clinical studies, a spectrum of expedited clinical trial modes has been designed, and selectively implemented in contemporary drug developing landscape. Herein this article presents an update on the innovated human trial designs that are corroborated through coming up with approval of notable therapeutic compounds for clinical utilization including delivery of several blockbuster products. It is intended to inspire clinical investigators and pharmaceutical development not only timely communicating with the regulatory agencies, but also insightful translating from cutting-edge scientific discoveries.

PubMed Disclaimer

References

    1. Bothwell LE, Greene JA, Podolsky SH. Assessing the gold standard–lessons from the history of RCTs. N Engl J Med. 2016;374:2175–2181. - PubMed
    1. Cescon D, Siu LL. Cancer clinical trials: the rear-view mirror and the crystal ball. Cell. 2017;168:575–578. - PubMed
    1. Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med. 2016;375:65–74. - PubMed
    1. Warren JB. Generics, chemisimilars and biosimilars: is clinical testing fit for purpose? Br J Pharmacol. 2012;75:7–14. - PMC - PubMed
    1. Huang B, Barber SL, Xu M, Cheng S. Make up a missed lesson-New policy to ensure the interchangeability of generic drugs in China. Pharmacol Res Perspect. 2017;5:e00318. - PMC - PubMed